Furthermore, rapamycin, a therapeutic agent with both immunosuppressant and antitumor properties [42], reduced the proliferation of glioblastoma cells and increased the expression of neural differentiation markers (GFAP and βIII-tubulin) [12]. The gene discussed is GFAP; the disease is glioblastoma.